New therapies show promise in treating diabetes New updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes. New device could be breakthrough for diabetics January 02, 2017 By Christine Blank FDA recently expanded approval of the G5 Mobile Continuous Glucose Monitoring System (Dexcom) to allow for replacement of fingerstick blood glucose (sugar) testing for diabetics. Biosensors in contact lenses can monitor IOP and diabetes October 05, 2016 By Laird Harrison Work is progressing on contact lenses that can monitor biomarkers in tear film for intraocular pressure, diabetes mellitus, and other health conditions. Patient navigators can benefit diabetes outcomes Study seeks to determine whether significant improvement in glycemic control can be achieved when regular coaching is part of the process. Outer retinal layer thickness predicts visual acuity in diabetic macular oedema Diabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents. First “follow-on” insulin glargine product approved to treat diabetes December 21, 2015 By Erin Bastick FDA approved insulin glargine injection (Basaglar, Eli Lilly) to improve glycemic control in patients with diabetes mellitus. Night-shift workers, poor sleepers at risk for diabetes December 11, 2015 By Rachael Zimlich RN Third-shift work may not be recognized as a risk factor for developing diabetes, but poor sleep patterns could contribute, says a new report. Interval exercise ideal to thwart diabetes development November 23, 2015 By Rachael Zimlich RN Thirty minutes of high-intensity interval exercise five days a week can delay diabetes development, according to new research. First 2-drug combo for advanced melanoma, plus 5 more FDA actions October 07, 2015 By Christine Blank First 2-drug therapy approved for advanced melanoma and four other recent approvals by FDA relating to new drugs and treatments. FDA approves long-acting insulin drugs September 28, 2015 By Erin Bastick FDA approved Tresiba (insulin degludec injection, Novo Nordisk) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection, Novo Nordisk) for the treatment of diabetes mellitus.